Invest1 distinct publisher3 min readPublished
Bayer, Corteva, Syngenta and BASF now clear the concentration thresholds economists treat as scrutiny-worthy, and the exposure that follows sits in patent scope and pricing, not in a blocked merger.
The Investor · Invest desk
Compiled by The InvestorSomething wrong?How this is made
The 40% and 60% marks are rules of thumb, not statutes. Fortune reports that economists treat 40% combined share among a sector's top four firms as the point where market distortions begin, and 60% as the level that draws heightened antitrust scrutiny [3]. Measured that way, the seed figure clears the lower line by 16 points and the pesticide figure clears the higher one by a single point [1].
That reads badly and forecasts poorly, because the structure was assembled with regulators in the room. Dow and DuPont folded their agricultural divisions into Corteva, and China National Chemical bought Syngenta before merging it with Sinochem's farm assets [16]. BASF has a seed business at all because regulators made Bayer sell canola, soybean and vegetable lines as the price of approving the $63 billion Monsanto purchase in 2018 [8][7]. The fourth name in the four-firm count is a remedy. An authority returning to this sector is not reviewing a transaction; it is reviewing behaviour inside a shape it already signed off.
Global averages also flatter it. In US corn seed, Corteva sits at 38.3% and Bayer at 33.3% [4], which is 71.6% between two companies, past the scrutiny level without needing the other two [2]. Bayer's 23% of world seeds [2] is 41% of the entire four-firm total [4].
What turns share into recurring cash is patent scope. Traditional plant variety rights let a farmer keep seed from their own harvest for personal use; utility patents, the stronger protection now extending into gene-edited crops, carry no such exemption, and a grower who replants without a licence can be sued whether they bought the seed or grew it themselves [11]. That is a legal construct, not a plant. The bundling logic was stated openly at the outset: Monsanto's then-chief executive described the merger wave as selling farmers seeds, chemicals and data as one package rather than components they could mix and match [17].
Which is why an unpriced workshop in the Marche hills is worth a line in an investment note. The network's Distributed Seed House operates on a gift economy with no joining fee, distributing material that is neither patented nor genetically modified [13], against an FAO estimate that roughly 75% of crop genetic diversity has been lost over the past century [15]. In tonnage it is nothing. As a signal it shows enforcement of seed licences becoming a subject people organise around rather than a clause they sign.
One caution on the arithmetic: these share figures come from a single publication's reporting [1] rather than an audited filing, and concentration numbers move by a few points depending on what gets counted as a market. The direction is not in dispute; the precise distance above the line is.
Ranked by verification strength, evidence, and original report placement.
Bayer, Corteva, Syngenta and BASF control 56% of the world's commercial seed market and 61% of its pesticide market.
Bayer alone holds 23% of the global seed market.
Economists typically flag 40% combined share among a sector's top four firms as the point where market distortions start, and 60% as the threshold that draws heightened antitrust scrutiny.
In the US, Corteva controls 38.3% of corn seed and Bayer 33.3%.
Four firms control 93.6% of US cotton seed, with Bayer alone at 38.4%.
Bayer and BASF together hold patents covering 90% of trait acres across corn, soybeans and cotton.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Specific numbers, single unattributed source
Every claim rests on one publisher. The quantitative spine — 56%/61% global shares, 38.3%/33.3% US corn, 93.6% US cotton, 90% of trait acres, 75% diversity loss — is precise but carries no primary citation, dataset, or date in the supplied text, and no company or regulator response appears. The best-corroborated items are the widely documented transaction and litigation facts (the $63 billion Monsanto purchase, the regulator-forced divestitures bought by BASF, more than $12 billion of Roundup settlements). The legal contrast between plant variety rights and utility patents is stated as a general rule without statute or case citation.
Incumbent share documented, counter-movement anecdotal
Adoption is asymmetric. On the incumbent side, uptake is effectively measured by market share: a majority of commercial seed and pesticide supply and 93.6% of US cotton seed, plus patents over 90% of trait acres. On the alternative side, observable uptake is two soft signals — one sold-out August workshop with 1,600+ social sign-ons and a 2026 calendar reported to sell out quickly — with no membership counts, acreage, or seed volumes. Nothing in the source shows patent-free seed networks displacing commercial supply at measurable scale.
Framing runs ahead of the counter-movement evidence
The structural claims are close to their evidence: the shares as reported do clear the thresholds the article cites, and the litigation figures are concrete. The overstatement sits in two places. First, threshold-crossing is presented as scrutiny-worthy exposure while no antitrust proceeding, pricing series, or regulatory action is shown, so the pricing-power consequence is asserted rather than measured. Second, a single sold-out farmhouse workshop is framed as a 'front line' against four multinationals, with no scale data behind it. Positive but moderate, because the numbers themselves are not inflated — only the inferences drawn from them.
Interested voices on both sides of the story
The named non-corporate voices have stakes in the outcome: the workshop was led by the technical director of Arcoiris Sementi Bio, an organic seed company that competes with patented commercial varieties, and the critical quotes come from the coordinator of a food-sovereignty advocacy organisation. On the corporate side the source itself documents an incentive conflict — Monsanto seeking tariffs on a glyphosate ingredient days after farm groups backed Bayer in court, which those groups said would raise their costs — and traces the consolidation logic to a stated strategy of bundling seeds, chemicals and data. No company was given space to respond, so only one set of incentives is interrogated.
Plausible and internally consistent, but uncorroborated
Confidence is limited by cluster structure rather than internal coherence. The article is self-consistent and its derived arithmetic checks out against its own figures, and the transaction and settlement facts are of a kind that is routinely documented elsewhere. But one publisher supplies everything, the share and patent statistics are unsourced, no company or regulator is heard, and the alternative-network uptake rests on undated anecdote. That combination supports directional confidence in the concentration picture and low confidence in the pricing and displacement inferences.
science
Two-thirds want glyphosate banned, and almost nobody has been reading about it1 distinct publisher
science
No country is on track to cut food system emissions by 2030, first goal-referenced audit finds1 distinct publisher
invest
Spinach doubled in a month: Korea's heat shock is a price mechanism, not a weather story1 distinct publisher
invest
Zhu Rongji's obituary is a bull case on Chinese demand. Test it before you buy it1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.